Compare TYRA & WWW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TYRA | WWW |
|---|---|---|
| Founded | 2018 | 1883 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2021 | 2003 |
| Metric | TYRA | WWW |
|---|---|---|
| Price | $22.30 | $21.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $47.45 | $24.30 |
| AVG Volume (30 Days) | 563.7K | ★ 923.9K |
| Earning Date | 11-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | ★ 1.88% |
| EPS Growth | N/A | ★ 96.55 |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $1,874,300,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | N/A | $5.83 |
| P/E Ratio | ★ N/A | $35.07 |
| Revenue Growth | N/A | ★ 6.80 |
| 52 Week Low | $13.83 | $14.00 |
| 52 Week High | $40.65 | $23.84 |
| Indicator | TYRA | WWW |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 59.51 |
| Support Level | $18.46 | $18.98 |
| Resistance Level | $22.37 | N/A |
| Average True Range (ATR) | 1.04 | 0.90 |
| MACD | 0.27 | 0.17 |
| Stochastic Oscillator | 76.27 | 58.59 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; and Work Group. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear. Geographically, the company operates in United States; Europe, Middle East and Africa; Asia Pacific; Canada; and Latin America.